MX2016014178A - Composiciones de oligonucleotidos y metodos para realizarlas. - Google Patents
Composiciones de oligonucleotidos y metodos para realizarlas.Info
- Publication number
- MX2016014178A MX2016014178A MX2016014178A MX2016014178A MX2016014178A MX 2016014178 A MX2016014178 A MX 2016014178A MX 2016014178 A MX2016014178 A MX 2016014178A MX 2016014178 A MX2016014178 A MX 2016014178A MX 2016014178 A MX2016014178 A MX 2016014178A
- Authority
- MX
- Mexico
- Prior art keywords
- free
- amino group
- methods
- compositions
- protected
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 125000003277 amino group Chemical group 0.000 abstract 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 2
- 230000008878 coupling Effects 0.000 abstract 2
- 238000010168 coupling process Methods 0.000 abstract 2
- 238000005859 coupling reaction Methods 0.000 abstract 2
- 239000000539 dimer Substances 0.000 abstract 2
- 239000002777 nucleoside Substances 0.000 abstract 2
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract 2
- 229920013631 Sulfar Polymers 0.000 abstract 1
- 238000010511 deprotection reaction Methods 0.000 abstract 1
- 239000012011 nucleophilic catalyst Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 abstract 1
- 239000007790 solid phase Substances 0.000 abstract 1
- 238000010532 solid phase synthesis reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
- C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente descripción proporciona un método de fase sólida para realizar oligonucleótidos mediante ciclos de acoplamiento secuenciales que incluyen al menos un acoplamiento de una subunidad de dímero de dinucleótido con un grupo de extremo 3' libre de una cadena en crecimiento. Los oligonucleótidos incluyen al menos dos subunidades de nucleósido unidas por un enlace fosforamidato N3´?P5´. El método puede incluir los pasos de (a) desproteger el grupo amino 3' protegido de un nucleósido de extremo unido a un soporte de fase sólida, dicha desprotección forma un grupo amino 3' libre; (b) poner en contacto el grupo amino 3' libre con un dímero de amino-dinucleótido-5'-fosforamidit a 3' protegido en presencia de un catalizador nucleofilico para formar un enlace de fosforamidita N3'?P5' internucleósido; y (c) oxidar (por ejemplo, sulfar) el enlace. Las composiciones producidas por los métodos de la presente pueden incluir una cantidad reducida de uno o más productos de oligonucléotido (N-x). También se proporcionan composiciones farmacéuticas que incluyen las composiciones de oligonucleótido de la presente.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461987396P | 2014-05-01 | 2014-05-01 | |
| US201562151909P | 2015-04-23 | 2015-04-23 | |
| PCT/US2015/028327 WO2015168310A1 (en) | 2014-05-01 | 2015-04-29 | Oligonucleotide compositions and methods of making the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016014178A true MX2016014178A (es) | 2017-05-04 |
| MX382233B MX382233B (es) | 2025-03-13 |
Family
ID=54359301
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016014178A MX382233B (es) | 2014-05-01 | 2015-04-29 | Composiciones de oligonucleotidos y metodos para realizarlas. |
| MX2021004932A MX2021004932A (es) | 2014-05-01 | 2016-10-28 | Composiciones de oligonucleotidos y metodos para realizarlas. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021004932A MX2021004932A (es) | 2014-05-01 | 2016-10-28 | Composiciones de oligonucleotidos y metodos para realizarlas. |
Country Status (33)
| Country | Link |
|---|---|
| US (6) | US9796747B2 (es) |
| EP (2) | EP4286519A3 (es) |
| JP (7) | JP7040892B2 (es) |
| KR (4) | KR20230088509A (es) |
| CN (3) | CN111228288B (es) |
| AP (1) | AP2016009489A0 (es) |
| AU (3) | AU2015253158B2 (es) |
| BR (1) | BR112016025196B1 (es) |
| CL (4) | CL2016002749A1 (es) |
| DK (1) | DK3137479T5 (es) |
| EA (1) | EA034882B9 (es) |
| ES (1) | ES2963740T3 (es) |
| FI (1) | FI3137479T3 (es) |
| HR (1) | HRP20231505T1 (es) |
| HU (1) | HUE064289T2 (es) |
| IL (2) | IL248044B (es) |
| JO (2) | JOP20200257A1 (es) |
| LT (1) | LT3137479T (es) |
| MA (1) | MA63525B1 (es) |
| MX (2) | MX382233B (es) |
| MY (2) | MY178617A (es) |
| PE (1) | PE20170147A1 (es) |
| PH (1) | PH12016502080A1 (es) |
| PL (1) | PL3137479T3 (es) |
| PT (1) | PT3137479T (es) |
| RS (1) | RS64860B1 (es) |
| SG (2) | SG11201608226YA (es) |
| SI (1) | SI3137479T1 (es) |
| SM (1) | SMT202300405T1 (es) |
| TW (2) | TWI712413B (es) |
| UA (1) | UA126108C2 (es) |
| WO (1) | WO2015168310A1 (es) |
| ZA (2) | ZA201606624B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS61840B1 (sr) | 2004-07-02 | 2021-06-30 | Geron Corp | Sinteza zaštićenih 3'-amino 5'-fosforamidit nukleozidnih monomera |
| JOP20200257A1 (ar) * | 2014-05-01 | 2017-06-16 | Geron Corp | تركيبات أوليجو نوكليوتيد وطرق لتحضيرها |
| JP2018513127A (ja) | 2015-04-23 | 2018-05-24 | ジェロン・コーポレーションＧｅｒｏｎ Ｃｏｒｐｏｒａｔｉｏｎ | 多価カチオン塩組成物を用いたポリヌクレオチド調製方法 |
| ES2901099T3 (es) * | 2017-07-10 | 2022-03-21 | Geron Corp | Proceso mejorado para la preparación de imetelstat |
| KR102982955B1 (ko) | 2019-10-28 | 2026-06-29 | 제론 코포레이션 | 3-팔미토일-아미도-1,2-프로판다이올 및 3-팔미토일-아미도-2-하이드록시-1-다이메톡시트라이페닐메틸에터-프로판의 결정질 고체 및 이의 제조 및 사용 방법 |
| IL292328B2 (en) * | 2019-10-28 | 2025-10-01 | Geron Corp | Succinylate-converted 3-(amido fatty acid)-2-hydroxy-1-(protected hydroxy)-propane salts, amorphous solids and methods for their preparation |
| JP7657736B2 (ja) * | 2020-01-08 | 2025-04-07 | 日東電工株式会社 | セグメント型アミダイトを用いた核酸合成法 |
| WO2023069865A1 (en) | 2021-10-15 | 2023-04-27 | Codexis, Inc. | Engineered terminal deoxynucleotidyl transferase variants |
| KR20250008345A (ko) | 2023-07-07 | 2025-01-14 | 주식회사 엘지에너지솔루션 | 체결기구 및 체결기구를 포함하는 전지팩 |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4046720A (en) | 1974-01-17 | 1977-09-06 | California Institute Of Technology | Crosslinked, porous, polyacrylate beads |
| US4394448A (en) | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
| US4413070A (en) | 1981-03-30 | 1983-11-01 | California Institute Of Technology | Polyacrolein microspheres |
| US4678814A (en) | 1981-03-30 | 1987-07-07 | California Institute Of Technology | Polyacrolein microspheres |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US6448392B1 (en) | 1985-03-06 | 2002-09-10 | Chimerix, Inc. | Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use |
| US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| US4757141A (en) | 1985-08-26 | 1988-07-12 | Applied Biosystems, Incorporated | Amino-derivatized phosphite and phosphate linking agents, phosphoramidite precursors, and useful conjugates thereof |
| US4659774A (en) | 1985-11-01 | 1987-04-21 | American Hoechst Corporation | Support for solid-phase oligonucleotide synthesis |
| US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
| WO1990010448A2 (en) | 1989-03-07 | 1990-09-20 | Genentech, Inc. | Covalent conjugates of lipid and oligonucleotide |
| US4958013A (en) | 1989-06-06 | 1990-09-18 | Northwestern University | Cholesteryl modified oligonucleotides |
| US5411947A (en) | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
| US6395492B1 (en) | 1990-01-11 | 2002-05-28 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
| US6153737A (en) | 1990-01-11 | 2000-11-28 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
| US6114513A (en) | 1990-01-11 | 2000-09-05 | Isis Pharmaceuticals, Inc. | Thiol-derivatized oligonucleotides |
| AU7759291A (en) | 1990-03-29 | 1991-10-21 | Gilead Sciences, Inc. | Oligonucleotide-transport agent disulfide conjugates |
| US5420330A (en) | 1990-09-07 | 1995-05-30 | Pharmacia P-L Biochemicals Inc. | Lipo-phosphoramidites |
| US5419966A (en) | 1991-06-10 | 1995-05-30 | Microprobe Corporation | Solid support for synthesis of 3'-tailed oligonucleotides |
| US5633360A (en) | 1992-04-14 | 1997-05-27 | Gilead Sciences, Inc. | Oligonucleotide analogs capable of passive cell membrane permeation |
| US5629154A (en) | 1993-11-12 | 1997-05-13 | Geron Corporation | Telomerase activity assays |
| US5489508A (en) | 1992-05-13 | 1996-02-06 | University Of Texas System Board Of Regents | Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
| US5837453A (en) | 1992-05-13 | 1998-11-17 | Geron Corporation | Telomerase activity assays |
| US6235886B1 (en) | 1993-09-03 | 2001-05-22 | Isis Pharmaceuticals, Inc. | Methods of synthesis and use |
| IL107150A0 (en) | 1992-09-29 | 1993-12-28 | Isis Pharmaceuticals Inc | Oligonucleotides having a conserved g4 core sequence |
| US7067497B2 (en) | 1992-09-29 | 2006-06-27 | Isis Pharmaceuticals, Inc. | Modulation of telomere length by oligonucleotides having a G-core sequence |
| US6087491A (en) | 1993-01-08 | 2000-07-11 | Hybridon, Inc. | Extremely high purity oligonucleotides and methods of synthesizing them using dimer blocks |
| US5476925A (en) | 1993-02-01 | 1995-12-19 | Northwestern University | Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups |
| US6350853B1 (en) | 1993-04-26 | 2002-02-26 | Peter E. Nielsen | Conjugated peptide nucleic acids having enhanced cellular uptake |
| DE4331670A1 (de) | 1993-09-17 | 1995-03-23 | Hoechst Ag | Neue Antisense-Oligonucleotide gegen HSV-1 sowie deren Herstellung |
| WO1995011253A1 (en) | 1993-10-18 | 1995-04-27 | The Walter And Eliza Hall Institute Of Medical Research | A method for enhancing neurone survival and agents useful for same |
| US5863726A (en) | 1993-11-12 | 1999-01-26 | Geron Corporation | Telomerase activity assays |
| US5726297A (en) | 1994-03-18 | 1998-03-10 | Lynx Therapeutics, Inc. | Oligodeoxyribonucleotide N3' P5' phosphoramidates |
| US5599922A (en) | 1994-03-18 | 1997-02-04 | Lynx Therapeutics, Inc. | Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties |
| HUT76094A (en) | 1994-03-18 | 1997-06-30 | Lynx Therapeutics | Oligonucleotide n3'-p5' phosphoramidates: synthesis and compounds; hybridization and nuclease resistance properties |
| GB9413035D0 (en) | 1994-06-29 | 1994-08-17 | Scras | Antisense oligonucleeotides |
| US5583016A (en) | 1994-07-07 | 1996-12-10 | Geron Corporation | Mammalian telomerase |
| JPH10505488A (ja) | 1994-07-07 | 1998-06-02 | ジェロン コーポレイション | 哺乳動物のテロメラーゼ |
| US5958680A (en) | 1994-07-07 | 1999-09-28 | Geron Corporation | Mammalian telomerase |
| JPH10509447A (ja) | 1994-11-07 | 1998-09-14 | ハイブライドン インコーポレイテッド | ３ｈ−１，２−ベンゾジチオール−３−１，１−ジオキシドを用いた▲上３５▼ｓ−標識オリゴヌクレオチドの合成 |
| US5656638A (en) | 1995-04-18 | 1997-08-12 | Geron Corporation | Telomerase inhibitors |
| US5863936A (en) | 1995-04-18 | 1999-01-26 | Geron Corporation | Telomerase inhibitors |
| US5760062A (en) | 1995-04-18 | 1998-06-02 | Geron Corporation | Telomerase inhibitors |
| US5840490A (en) | 1995-06-07 | 1998-11-24 | Mcmaster University | Telomerase activity associated with hematological and colorectal malignancies |
| US5770613A (en) | 1995-09-29 | 1998-06-23 | Geron Corporation | Telomerase inhibitors |
| US5767278A (en) | 1995-10-06 | 1998-06-16 | Geron Corporation | Telomerase inhibitors |
| US5859233A (en) | 1996-02-21 | 1999-01-12 | Lynx Therapeutics, Inc. | Synthons for synthesis of oligonucleotide N3-P5 phosphoramidates |
| US5684143A (en) | 1996-02-21 | 1997-11-04 | Lynx Therapeutics, Inc. | Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates |
| GB9606158D0 (en) | 1996-03-23 | 1996-05-29 | Ciba Geigy Ag | Chemical compounds |
| US6015710A (en) | 1996-04-09 | 2000-01-18 | The University Of Texas System | Modulation of mammalian telomerase by peptide nucleic acids |
| WO1997037691A1 (en) * | 1996-04-10 | 1997-10-16 | Lynx Therapeutics, Inc. | Telomerase inhibitors |
| US6111085A (en) | 1996-09-13 | 2000-08-29 | Isis Pharmaceuticals, Inc. | Carbamate-derivatized nucleosides and oligonucleosides |
| US6444650B1 (en) | 1996-10-01 | 2002-09-03 | Geron Corporation | Antisense compositions for detecting and inhibiting telomerase reverse transcriptase |
| US6261836B1 (en) | 1996-10-01 | 2001-07-17 | Geron Corporation | Telomerase |
| US6001991A (en) | 1996-10-04 | 1999-12-14 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression |
| EP0951568A1 (en) | 1996-12-20 | 1999-10-27 | Geron Corporation | Methods for detecting and inhibiting the rna component of telomerase |
| US5846723A (en) | 1996-12-20 | 1998-12-08 | Geron Corporation | Methods for detecting the RNA component of telomerase |
| US5877309A (en) | 1997-08-13 | 1999-03-02 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides against JNK |
| US5998604A (en) | 1997-09-15 | 1999-12-07 | The Perkin-Elmer Corporation | Polynucleotide purification method |
| JP3722630B2 (ja) | 1998-10-28 | 2005-11-30 | パイオニア株式会社 | 記録再生装置 |
| US6656730B1 (en) | 1999-06-15 | 2003-12-02 | Isis Pharmaceuticals, Inc. | Oligonucleotides conjugated to protein-binding drugs |
| HK1049339B (en) | 1999-09-10 | 2008-06-27 | Geron Corporation | Oligonucleotide n3'-p5' thiophosphoramidates: their synthesis and use |
| GB9927674D0 (en) * | 1999-11-23 | 2000-01-19 | Aegis Eng Ltd | Protective material |
| US6331399B1 (en) | 2000-05-16 | 2001-12-18 | Isis Pharmaceuticals, Inc. | Antisense inhibition of tert expression |
| US7563618B2 (en) | 2001-03-23 | 2009-07-21 | Geron Corporation | Oligonucleotide conjugates |
| AU2002245717A1 (en) | 2001-03-23 | 2002-10-08 | Geron Corporation | Oligonucleotide conjugates |
| US20120329858A1 (en) | 2010-08-04 | 2012-12-27 | Geron Corporation | Modified oligonucleotides for telomerase inhibition |
| DK3342425T3 (da) | 2003-09-09 | 2020-03-16 | Geron Corp | Modificerede oligonukleotider til inhibering af telomerase |
| RS61840B1 (sr) | 2004-07-02 | 2021-06-30 | Geron Corp | Sinteza zaštićenih 3'-amino 5'-fosforamidit nukleozidnih monomera |
| WO2006023880A2 (en) * | 2004-08-23 | 2006-03-02 | Isis Pharmaceuticals, Inc. | Compounds and methods for the characterization of oligonucleotides |
| AU2005295351A1 (en) * | 2004-10-18 | 2006-04-27 | Codon Devices, Inc. | Methods for assembly of high fidelity synthetic polynucleotides |
| EP1876893B1 (en) | 2005-04-15 | 2012-04-11 | Geron Corporation | Cancer treatment by combined inhibition of proteasome and telomerase activities |
| WO2007127163A2 (en) * | 2006-04-24 | 2007-11-08 | Geron Corporation | Cns-tumor treatment method and composition |
| EP4600359A2 (en) | 2006-10-30 | 2025-08-13 | Geron Corporation | Combined telomerase inhibitor and gemcitabine for the treatment of cancer |
| WO2008094640A2 (en) * | 2007-01-30 | 2008-08-07 | Geron Corporation | Compounds having anti-adhesive effects on cancer cells |
| US9106103B2 (en) | 2011-09-23 | 2015-08-11 | Eaton Corporation | Unintteruptible power supply systems and methods employing on-demand energy storage |
| US9006630B2 (en) | 2012-01-13 | 2015-04-14 | Altasens, Inc. | Quality of optically black reference pixels in CMOS iSoCs |
| US9375485B2 (en) | 2012-12-07 | 2016-06-28 | Geron Corporation | Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms |
| US20150342982A1 (en) | 2012-12-07 | 2015-12-03 | Geron Corporation | Use of Telomerase Inhibitors for the Treatment of Myeloproliferative Disorders and Myeloproliferative Neoplasms |
| JOP20200257A1 (ar) | 2014-05-01 | 2017-06-16 | Geron Corp | تركيبات أوليجو نوكليوتيد وطرق لتحضيرها |
-
2014
- 2014-05-01 JO JOP/2020/0257A patent/JOP20200257A1/ar unknown
-
2015
- 2015-04-29 MY MYPI2016703971A patent/MY178617A/en unknown
- 2015-04-29 WO PCT/US2015/028327 patent/WO2015168310A1/en not_active Ceased
- 2015-04-29 ES ES15785822T patent/ES2963740T3/es active Active
- 2015-04-29 HR HRP20231505TT patent/HRP20231505T1/hr unknown
- 2015-04-29 TW TW108147051A patent/TWI712413B/zh active
- 2015-04-29 EP EP23193452.2A patent/EP4286519A3/en active Pending
- 2015-04-29 MY MYPI2020002421A patent/MY196927A/en unknown
- 2015-04-29 MA MA63525A patent/MA63525B1/fr unknown
- 2015-04-29 KR KR1020237018801A patent/KR20230088509A/ko not_active Ceased
- 2015-04-29 AP AP2016009489A patent/AP2016009489A0/en unknown
- 2015-04-29 SG SG11201608226YA patent/SG11201608226YA/en unknown
- 2015-04-29 UA UAA201610381A patent/UA126108C2/uk unknown
- 2015-04-29 PE PE2016002150A patent/PE20170147A1/es unknown
- 2015-04-29 KR KR1020167029996A patent/KR102316282B1/ko active Active
- 2015-04-29 EA EA201691786A patent/EA034882B9/ru unknown
- 2015-04-29 US US14/699,902 patent/US9796747B2/en active Active
- 2015-04-29 CN CN202010050944.5A patent/CN111228288B/zh active Active
- 2015-04-29 KR KR1020217033531A patent/KR102707216B1/ko active Active
- 2015-04-29 PL PL15785822.6T patent/PL3137479T3/pl unknown
- 2015-04-29 LT LTEPPCT/US2015/028327T patent/LT3137479T/lt unknown
- 2015-04-29 MX MX2016014178A patent/MX382233B/es unknown
- 2015-04-29 DK DK15785822.6T patent/DK3137479T5/da active
- 2015-04-29 SG SG10201911086XA patent/SG10201911086XA/en unknown
- 2015-04-29 HU HUE15785822A patent/HUE064289T2/hu unknown
- 2015-04-29 CN CN201580022353.4A patent/CN106459134B/zh active Active
- 2015-04-29 SI SI201531963T patent/SI3137479T1/sl unknown
- 2015-04-29 AU AU2015253158A patent/AU2015253158B2/en active Active
- 2015-04-29 JP JP2016564990A patent/JP7040892B2/ja active Active
- 2015-04-29 CN CN202311295220.7A patent/CN117357548A/zh active Pending
- 2015-04-29 RS RS20231110A patent/RS64860B1/sr unknown
- 2015-04-29 BR BR112016025196-2A patent/BR112016025196B1/pt active IP Right Grant
- 2015-04-29 JO JOP/2015/0089A patent/JO3767B1/ar active
- 2015-04-29 TW TW104113709A patent/TWI709406B/zh active
- 2015-04-29 EP EP15785822.6A patent/EP3137479B1/en active Active
- 2015-04-29 PT PT157858226T patent/PT3137479T/pt unknown
- 2015-04-29 FI FIEP15785822.6T patent/FI3137479T3/fi active
- 2015-04-29 KR KR1020247031813A patent/KR20240144488A/ko active Pending
- 2015-04-29 SM SM20230405T patent/SMT202300405T1/it unknown
-
2016
- 2016-09-23 ZA ZA2016/06624A patent/ZA201606624B/en unknown
- 2016-09-26 IL IL248044A patent/IL248044B/en active IP Right Grant
- 2016-10-19 PH PH12016502080A patent/PH12016502080A1/en unknown
- 2016-10-28 CL CL2016002749A patent/CL2016002749A1/es unknown
- 2016-10-28 MX MX2021004932A patent/MX2021004932A/es unknown
-
2017
- 2017-09-14 US US15/705,019 patent/US10392418B2/en active Active
- 2017-09-14 US US15/705,021 patent/US11299511B2/en active Active
-
2018
- 2018-05-01 JP JP2018088277A patent/JP2018131453A/ja active Pending
- 2018-05-04 CL CL2018001213A patent/CL2018001213A1/es unknown
- 2018-05-04 CL CL2018001212A patent/CL2018001212A1/es unknown
-
2019
- 2019-08-07 IL IL268570A patent/IL268570B/en unknown
- 2019-12-25 JP JP2019234301A patent/JP2020050670A/ja not_active Withdrawn
-
2020
- 2020-03-06 AU AU2020201707A patent/AU2020201707B2/en active Active
- 2020-09-22 ZA ZA2020/05857A patent/ZA202005857B/en unknown
-
2021
- 2021-09-06 JP JP2021144677A patent/JP7736489B2/ja active Active
-
2022
- 2022-01-18 JP JP2022005584A patent/JP7308309B2/ja active Active
- 2022-01-26 CL CL2022000202A patent/CL2022000202A1/es unknown
- 2022-03-16 US US17/696,300 patent/US11739114B2/en active Active
- 2022-05-16 AU AU2022203273A patent/AU2022203273A1/en not_active Abandoned
-
2023
- 2023-04-03 JP JP2023060170A patent/JP2023073510A/ja not_active Withdrawn
- 2023-06-07 US US18/330,935 patent/US20240150391A1/en not_active Abandoned
-
2024
- 2024-01-05 US US18/405,775 patent/US20250011359A1/en not_active Abandoned
-
2025
- 2025-11-07 JP JP2025188613A patent/JP2026016798A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018001213A1 (es) | Composiciones de oligonocleótidos y métodos para realizarlas (divisional de sol. n°2749-16) | |
| BR112014009066B8 (pt) | molécula de ácido nucleico, método para a sintetização de uma molécula de dna de triciclo-fosforotioato e composição farmacêutica | |
| EA201490993A1 (ru) | МОДИФИЦИРОВАННЫЕ СРЕДСТВА РНКи | |
| CY1124632T1 (el) | Προϊοντα συζευξης αναλογων cc-1065 και διλειτουργικοι συνδετες | |
| ECSP14010277A (es) | Nucleósidos sustituidos, nucleótidos y análogos de los mismos | |
| MX2017016688A (es) | Nuevas enzimas y sistemas crispr. | |
| MX2016010717A (es) | Métodos y composiciones para el perfilado de adn. | |
| MX2016016905A (es) | Ensamblaje de adn mediado por nucleasa. | |
| CL2013002990A1 (es) | Compuestos derivados de imidazo[5,1-a]isoindol o sus sales, inhibidores de indolamina 2,3-dioxigenasa (ido); composicion farmaceutica, utiles para tratar la inmunosupresion asociada con una enfermedad infecciosa o cancer. | |
| ECSP11011391A (es) | Métodos y productos intermedios para preparar agentes farmacéuticos | |
| CR20140232A (es) | Agentes de iarn, composiciones y métodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr) | |
| PE20190626A1 (es) | Composiciones y metodos para modular la expresion del factor b del complemento | |
| CL2018001770A1 (es) | Composiciones de decil mercaptanos mezclados y uso de las mismas como colectoras de productos químicos de minería | |
| ECSP13012438A (es) | Proceso para preparar compuestos antivirales | |
| PE20141155A1 (es) | Analogos del acido epoxi-eicosatrienoico y metodos para hacer y de uso del mismo | |
| AR100946A1 (es) | Composiciones y métodos para regular la expresión génica por medio de la interferencia de arn | |
| UY31871A (es) | Compuestos que comprenden un grupo ciclobutoxi | |
| CO2018013828A2 (es) | Composiciones farmacéuticas de oligómero de morfolino fósforodiamidato | |
| CR20110524A (es) | Proceso para preparar compuestos antivirales | |
| AR100235A1 (es) | Composiciones de oligonucleótidos y métodos para realizarlas | |
| CL2013003466A1 (es) | Construcción de arn que comprende una secuencia de segmento sentido y una antisentido del gen p0 del genoma del virus del amarilleo moderado de la remolacha (bmyv), metodo para inducir tolerancia al virus bmyv. | |
| AR086925A1 (es) | Metodos, composiciones y kits para determinar el virus de la inmunodeficiencia humana (vih) | |
| CL2020000054A1 (es) | Proceso mejorado para preparar imetelstat. | |
| EA202090282A1 (ru) | Композиции олигонуклеотидов и способы их получения | |
| TH166778A (th) | องค์ประกอบโอลิโกนิวคลีโอไทด์และวิธีการในการทำองค์ประกอบนี้ |